CDC Establishes New Workgroup to Study the Safety of Aluminum in Childhood Vaccines

By James Lyons-Weiler, Science and Medicine Contributor, The MAHA Report

The U.S. Centers for Disease Control and Prevention (CDC), through its Advisory Committee on Immunization Practices (ACIP), has established the Childhood and Adolescent Immunization Schedule Workgroup with a mandate to study aluminum adjuvants – salts – in some vaccines given to children.

As of October 8, 2025, CDC’s newly revised Terms of Reference (ToR) include ingredient-specific safety evaluations, with a direct focus on aluminum adjuvants and associated risks, including asthma.

The updated Terms of Reference asks: “Do either of the two different aluminum adjuvants increase the risk of asthma?” This language marks the first formal acknowledgment by ACIP that aluminum hydroxide and aluminum phosphate, the primary adjuvants in most pediatric vaccines, may merit differentiated toxicological scrutiny. This change places the issue within the Workgroup’s formal priority and scope, not as a fringe or side issue.